Cubist Pharmaceuticals (CBST -2%) dips after its Q3 misses estimates. Profit slid 53% Y/Y,...

|By:, SA News Editor

Cubist Pharmaceuticals (CBST -2%) dips after its Q3 misses estimates. Profit slid 53% Y/Y, largely due to acquisition-related costs resulting from its $190M deal for constipation drug-maker Adolor last month.